ArticleCancer diagnosis & prognosis
Prognostic Significance of Combined PD-L1 Expression and Chemotherapeutic Status in Cholangiocarcinoma Patients.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Cholangiocarcinoma (CCA) is a malignant tumor with high mortality and recurrence rates after treatment. The discovery of prognostic markers is, therefore, essential for improving patient outcomes after treatment. This study aimed to investigate the prognostic value of membranous and cytoplasmic PD-L1 expression, individually and in combination. In addition, the combination of PD-L1 expression and chemotherapeutic status was also explored. Patients and Methods: The expression of PD-L1 was examined in 200 CCA patients using immunohistological staining, and its correlation with clinicopathological data was investigated using the Chi-squared test. Overall survival (OS) and recurrence-free survival (RFS) investigations were performed using Kaplan-Meier (log-rank) and Cox-regression analysis. Results: The results demonstrated that high PD-L1 expression in the membrane and low expression in the cytoplasm had a correlation with intrahepatic CCA and lymph node metastasis. Furthermore, these patients had shorter OS and RFS compared to other groups of patients. Moreover, when the expression of PD-L1 was combined with chemotherapeutic status, the result demonstrated that patients who had high expression of PD-L1 in the membrane with low expression of PD-L1 in the cytoplasm and did not receive adjuvant chemotherapy showed significantly shorter OS and RFS compared to other patients. This could be an independent prognostic factor for RFS and OS with HR 1.889 and 1.990, respectively. Conclusion: PD-L1 expression levels can serve as a valuable predictor of outcomes in CCA patients, especially when evaluated alongside chemotherapeutic status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.